Estimates of economic rates of return for the U.S. pharmaceutical industry, 1976-1987

Journal of Accounting and Public Policy

Volumn 15, Issue 4, 1996, Pages 327-346

  Baber, William R ^a   Kang, Sok Hyon ^b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0030525033     PISSN: 02784254     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-4254(96)00002-6     Document Type: Article

References (25)

1. Bublitz, B. and Ettredge, M. Jan. 1989. The information in discretionary outlays: Advertising, research, and development. The Accounting Review 64(1):108-124.
2. Clarke, D. Nov. 1976. Econometric measurement of the duration of advertising effect on sales. Journal of Marketing Research 13(4):345-357.
3. Clarkson, K. 1977. Intangible Capital and Rates of Return, Effects of Research and Development on Profitability. Washington, DC: American Enterprise Institute for Public Policy Research.
4. Comanor, W. Sept. 1986. The political economy of the pharmaceutical industry. Journal of Economic Literature 24(3):1178-1217.
5. Dixit, A. and Pindyck, R. 1994. Investment Under Uncertainty. Princeton, NJ: Princeton University Press.
6. Fisher, F. and McGowan, J. March 1983. On the misuse of accounting rates of return to infer monopoly profits. The American Economic Review 73(1):82-97.
7. Gordon, L. and Hamer, M. July 1988. Rates of return and cashflow profiles: An extension. The Accounting Review 68(3):514-521.
8. Grabowski, H. and Mueller, D. Autumn 1978. Industrial research and development, intangible capital stocks, and firm profit rates. The Bell Journal of Economics 9(2):328-343.
9. Grabowski, H. and Vernon, J. July 1990. A new look at the returns and risks to pharmaceutical R&D. Management Science 36(7):804-821.
10. Griner, E. and Stark, A. Winter 1988. Cash recovery rates, accounting rates of return, and the estimation of economic performance. Journal of Accounting and Public Policy 7(4):293-311.
11. Ijiri, Y. Summer 1978. Cash-flow accounting and its structure. Journal of Accounting, Auditing, and Finance 1(4):331-348.
12. Ijiri, Y. 1979. Convergence of cash recovery rate. In Quantitative Planning and Control. New York: Academic Press, pp. 259-267.
13. Ijiri, Y. March 1980. Recovery rate and cashflow accounting. Financial Executive 48(3):54-60.
14. Lee, T. and Stark, A. Spring 1987. Ijiri's cash flow accounting and capital budgeting. Accounting and Business Research 17(66):125-132.
15. Megna, P. and Mueller, D. Nov. 1991. Profit rates and intangible capital. Review of Economics and Statistics 73(4):632-642.
16. Montgomery, D. and Silk, A. June 1972. Estimating dynamic effects of market communications expenditures. Management Science 18(10):B485-B501.
17. Salamon, G. April 1982. Cash recovery rates and measures of firm profitability. The Accounting Review 57(2):292-302.
18. Salamon, G. June 1985. Accounting rates of return. The American Economic Review 75(3):495-504.
19. Stark, A. Spring 1987. On the observability of the cash recovery rate. Journal of Business Finance & Accounting 14(1):99-108.
20. Stark, A., Thomas, H. and Watson, I. April 1992. On the practical importance of systematic error in conditional IRRs. Journal of Business Finance & Accounting 19(3):407-424.
21. Stark, A. Sept. 1993. Problems in measuring the cash recovery rate and measurement error in estimates of the firm IRR. The European Accounting Review 2(2):199-218.
22. Stark, A. March 1994. Some analytics of why conditional IRRs can contain growth rate related measurement error. Journal of Business Finance & Accounting 21(2):219-230.
23. U.S. General Accounting Office. Feb. 1993. Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices Review Board, Report to the Chairman, Special Committee on Aging, U.S. Senate (GAO/HRD-93-51) Washington, DC.
24. U.S. General Accounting Office. Jan. 1994. Prescription Drugs: Companies Typically Charge More in the United States Than in the United Kingdom, Report to the Chairman, Subcommittee on Health and the Environment, Committee on Energy and Commerce, U.S. House of Representatives (GAO/HEHS-94-29). Washington, DC.
25. U.S. Office of Technology Assessment (OTA) Feb. 1993. Pharmaceutical R&D Costs, Risks, and Rewards. Washington, DC: U.S. Government Printing Office.